Human Trials Expand to Pretoria, South Africa

Issaquah, WA

Lazure Scientific, Inc. announced today the expansion of their prostate cancer clinical trial to Pretoria, South Africa. The first human in the expansion was treated using the Lazure Low Dose Alternating Current (LDAC) prostate cancer treatment device on February 13, 2014 at The Urology Hospital in Pretoria as part of Lazure’s Study of Feasibility of Low-Dose Alternating Electric Current as a Treatment for Low-Risk Prostate Cancer.

The trial expansion is a result of the successful results obtained to date in Lazure’s initial clinical site in Tbilisi, Georgia. The combined locations will ultimately treat a total of 46 patients as part of the studies.

“We are pleased to be expanding our human clinical trials to a second location. Our results to date have been encouraging and we are excited to be increasing our patient pool to verify our effectiveness on a larger scale. Additionally, we have not seen life altering side effects that are so prevalent in currently available prostate cancer treatments. As a result, we continue to believe that LDAC technology could represent a major shift in the way prostate cancer is treated throughout the world.” Remarked Lazure CEO Charles Hill.

LaZure Scientific, Inc. is a development stage medical device company pioneering LDAC Technology, a proprietary, breakthrough cancer treatment method that employs low dose, alternating electric current to preferentially destroy cancer cells. LaZure’s first treatment device using LDAC is designed to provide effective, whole-gland treatment of early stage prostate cancer without creating serious side effects such as impotence and incontinence. This device is currently for investigational use only and has not been cleared for use in the U.S. by the FDA. For more information about LaZure and LDAC Technology, contact LaZure Scientific, Inc. at 1-855-552-9873.

Sorry, comments are closed for this post.